Clinical and Patient-Reported Outcomes (PROs) in C-POST: A Phase 3 Trial of Adjuvant Cemiplimab Versus Placebo for High-Risk Cutaneous Squamous Cell Carcinoma (CSCC). J of Skin [Internet]. 2025 Nov. 10 [cited 2026 May 2];9(6):s688. Available from: https://skin.dermsquared.com/skin/article/view/3775